CASLOT TABLETS 6.25 mg

البلد: ماليزيا

اللغة: الإنجليزية

المصدر: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

العنصر النشط:

CARVEDILOL

متاح من:

RANBAXY (MALAYSIA) SDN. BHD.

INN (الاسم الدولي):

CARVEDILOL

الوحدات في الحزمة:

100Tablet Tablets

المصنعة من قبل:

RANBAXY (MALAYSIA) SDN. BHD.

خصائص المنتج

CASLOT TABLETS
(CARVEDILOL TABLETS)
COMPOSITION
CASLOT 6.25 MG
Each tablet contains
Carvedilol ………….6.25 mg
CASLOT 12.5 MG
Each tablet contains
Carvedilol ………….12.5 mg
CASLOT 25 MG
Each tablet contains
Carvedilol………….25.0 mg
PRODUCT DESCRIPTION
CASLOT 6.25 MG :
Yellow coloured, circular, biconvex, uncoated mottled
tablets with a score-line on one side and plain on the other.
CASLOT 12.5 MG :
Peach coloured, circular, biconvex, uncoated mottled
tablets with a score-line on one side and plain on the other.
CASLOT 25 MG :
White
to
off-white,
circular,
biconvex,
uncoated
mottled tablets with a score-line on one side and plain on the
other.
DESCRIPTION
Carvedilol is a nonselective
β
-adrenergic blocking agent with
α
1
-blocking activity.
It
is
chemically
designated
as
(±)-1-Carbazol-4-yloxy-3-[[2-(o-
methoxyphenoxy)ethyl]amino]-propan-2-ol. The molecular formula for
carvedilol
is C
24
H
26
N
2
O
4
and its molecular weight is 406.5. CARVEDILOL
PHARMACOLOGY
MECHANISM OF ACTION
Carvedilol
is
a
vasodilating
non-selective
β
-blocking
agent
with
antioxidant
properties.
Vasodilation
is
predominantly
mediated
through
α
1-
receptor
antagonism.
Carvedilol
reduces
the
peripheral
vascular
resistance
through
vasodilation and suppresses the renin-angiotensin-aldosterone system
through
β
-blockade. The activity of plasma renin is reduced and fluid retention
is rare.
Carvedilol has no intrinsic sympathomimetic activity and like
propranolol, it has
membrane stabilising properties. Carvedilol is a racemate of two
stereoisomers.
β
-blockade is attributed to the S(-) enantiomer; in contrast, both
enantiomers
exhibit
the
same
α
1
-blocking
activity.
Carvedilol
is
a
potent
antioxidant,
a
scavenger of reactive oxygen radicals and an anti-proliferative agent.
Reported clinical studies have shown that the balance of vasodilation
and
β
-
blockade provided by carvedilol results in the following effects:
− In hypertensive patients, a reduction in blood pressure is not
associated with a
concomitant increase in t